Abstract: Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine.
Type:
Grant
Filed:
March 30, 2015
Date of Patent:
June 6, 2017
Assignee:
Natural Alternatives International, Inc.
Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.
Type:
Grant
Filed:
February 19, 2014
Date of Patent:
May 30, 2017
Assignee:
The Regents of the University of Colorado
Abstract: Disclosed are methods of treating a muscle disease and improving normal muscle function by administering a therapeutically effective amount of an isoprenoid antibiotic. Also disclosed are methods of upregulating hnRNP L and hnRNP L targets by administering a therapeutically effective amount of an isoprenoid antibiotic. Methods of screening compounds for use in treating muscle disease and improving muscle function are also described.
Type:
Grant
Filed:
October 19, 2012
Date of Patent:
May 30, 2017
Assignees:
Tufts Medical Center, Inc., Children's Medical Center Corporation
Inventors:
Isabelle Draper, Louis M. Kunkel, Matthew S. Alexander, Alan S. Kopin
Abstract: The invention relates to antagonists of the cannabinoid receptor CBI for use in the treatment and prevention of diseases associated with neural dendritic abnormalities, such as Down's syndrome, Angelman's syndrome, Rett syndrome and tuberous sclerosis. More specifically, the invention provides a method of treatment or prevention of such diseases by the administration of the compound rimonabant.
Type:
Grant
Filed:
March 19, 2013
Date of Patent:
May 30, 2017
Assignee:
Universitat Pompeu Fabra
Inventors:
Andres Ozaita Mintegui, Arnau Busquets Garcia, Rafael Maldonado Lopez
Abstract: Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.
Type:
Grant
Filed:
July 24, 2015
Date of Patent:
May 30, 2017
Assignee:
EMORY UNIVERSITY
Inventors:
Christina Gavegnano, Raymond F. Schinazi
Abstract: Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Type:
Grant
Filed:
March 3, 2016
Date of Patent:
May 23, 2017
Assignee:
Pharmacyclics LLC
Inventors:
Ching W. Chong, Robert Kuehl, Heow Tan, Harisha Atluri
Abstract: The present invention relates to a method of antagonizing a 5-HT6 serotonin receptor, comprising administering to the cell a compound of formula 1.2, or a pharmaceutically acceptable salt thereof, wherein: R1 is a C1-C5 alkyl; R2i is independently hydrogen, halogen, a C1-C3 alkyl, CF3, OCF3 or OCH3; i is 1, 2, 3 or 4; Ar is an unsubstituted phenyl or a substituted phenyl substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, substituted amino group or trifluoromethyl; or Ar is a substituted or unsubstituted 6-membered aromatic heterocycle with one or two nitrogen atoms in the heterocycle. The invention also relates to pharmaceutical compositions and method for treating a cognitive disorder or neurodegenerative disease in a subject in need thereof comprising administering an effective dose to the subject of a compound of formula 1.2 according to claim 1, or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
July 3, 2015
Date of Patent:
May 23, 2017
Inventors:
Alexandre Vasilievich Ivachtchenko, Andrey Alexandrovich Ivashchenko, Nikolay Filippovich Savchuk
Abstract: This invention relates to methods for preventing infestations of animals and their environments with adult fleas by systemic administration of isoxazoline compounds.
Type:
Grant
Filed:
December 9, 2014
Date of Patent:
May 23, 2017
Assignee:
Intervet Inc.
Inventors:
Heike Williams, Hartmut Zoller, Anja Regina Heckeroth
Abstract: The present disclosure is drawn to topical formulations and related methods. In one embodiment, a topical formulation is provided that includes at least one corticosteroid, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate.
Type:
Grant
Filed:
December 22, 2014
Date of Patent:
May 9, 2017
Assignee:
Crescita Therapeutics Inc.
Inventors:
Edward T. Kisak, John M. Newsam, Dominic King-Smith, Pankaj Karande, Samir Mitragotri, Wade A. Hull, Ngoc Truc-Chi Vo
Abstract: Provided herein is a method of treating, preventing, or managing osteolysis in a subject, comprising administering to the subject a therapeutically effective amount of vitamin C, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in combination with vitamin K, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
Type:
Grant
Filed:
May 19, 2015
Date of Patent:
May 9, 2017
Assignee:
IC-MEDTECH CORPORATION
Inventors:
James M. Jamison, Thomas M. Miller, Deborah R. Neal, Mark William Kovacik, Michael John Askew, Richard Albert Mostardi
Abstract: The invention includes methods of treating a subject having hepatitis B viral (HBV) infection. In certain embodiments, the method of the invention comprises stimulating the innate cytokine response in macrophages, dendritic cells and/or liver non-parenchymal cells with small molecular STING agonists, thus suppressing HBV replication in hepatocytes. In other embodiments, the method of the invention can be used to treat chronic HBV infections. The invention further provides methods of identifying compounds useful in treating HBV infection in a subject.
Type:
Grant
Filed:
October 21, 2014
Date of Patent:
May 9, 2017
Assignee:
Drexel University
Inventors:
Jinhong Chang, Fang Guo, Timothy M. Block, Ju-Tao Guo
Abstract: A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
Abstract: The present description relates to methods of administering effective amounts of an anti-arrhythmic agent, e.g., dantrolene, azumolene or a pharmaceutically acceptable salt thereof, for the acute treatment of cardiac arrhythmias, e.g., atrial fibrillation, premature ventricular contraction, ventricular tachycardia or ventricular fibrillation, and prevention of subsequent cardiac arrhythmias, wherein the methods effectuate a reduction in morbidity and mortality.
Abstract: The present disclosure relates generally to insecticide formulations. The present disclosure relates more particularly to aqueous pymetrozine formulations that can be provided in concentrate form and methods for making them. In one aspect, the disclosure provides a composition including pymetrozine in particulate form; a first polymeric dispersing agent, the first polymeric dispersing agent being a copolymer of (a) a maleic acid monomer and (b) a hydrophobic monomer; and a second polymeric dispersing agent, the second polymeric dispersing agent being a copolymer of (a) a (meth)acrylic acid monomer, an ethylenically unsaturated dicarboxylic acid monomer or a combination thereof, (b) a (meth)acrylamido alkyl or aryl sulfonate monomer; and (c) a third monomer selected from one or more of vinylic compounds, (meth)acrylic esters, vinyl acetate, and substituted (meth)acrylamides.
Abstract: A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
Abstract: The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to method of treatment these certain types of cancer. In particular, the disclosure relates to the combined use of inhibitors of ROCK and proteins of the MAPK/ERK-pathway in the treatment of KRAS-, NRAS- or BRAF-mutated cancer, in particular in NRAS mutated melanoma.
Type:
Grant
Filed:
September 22, 2014
Date of Patent:
April 25, 2017
Assignee:
STITCHING HET NEDERLANDS KANKER INSTITUT—ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Inventors:
Daniel Simon Peeper, Marjon Antoinetta Smit, Celia Jill Vogel
Abstract: A method for treating tau-associated disease by administering a pharmaceutical composition comprising a quinoline derivative to a subject in need is disclosed. Particularly, a method for treating Alzheimer's disease by administering a pharmaceutical composition comprising a quinoline derivative to a subject in need is disclosed. The two disclosed quinoline derivatives have the inhibition effect for GSK-3? kinase activity, so as the two disclosed quinoline derivatives have the ability for inhibiting tau hyperphosphorylation or reducing tau aggregation.
Type:
Grant
Filed:
August 16, 2016
Date of Patent:
April 25, 2017
Assignee:
National Taiwan Normal University
Inventors:
Guey-Jen Lee-Chen, Hsiu-Mei Hsieh, Guan-Chiun Lee, Ying-Chieh Sun
Abstract: In one embodiment, the invention provides a method of treating a subject suffering from a breast cancer tumor which is non-responsive or intrinsically resistant to anti-estrogen therapy comprising administering a therapeutically effective amount of an inhibitor of alternative (ALT) non-homologous end joining (NHEJ) factor to the subject. In another embodiment the invention provides a method of treating a subject who suffers from a pancreatic cancer which is non-responsive to chemotherapy and/or radiation comprising co-administering a therapeutically effective amount of PARP1 inhibitor and a DNA ligase III? inhibitor to the subject. Related diagnostic methods, nucleic acid arrays, devices and kits are also provided.
Type:
Grant
Filed:
July 8, 2015
Date of Patent:
April 18, 2017
Assignees:
STC.UNM, UNIVERSITY OF MARYLAND, BALTIMORE